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Abstract
The prostate carcinoma affect the quality of life of most male patients, includ-
ing in particular their sexual and emotional life. The aim of study was to assess 
sexual and psychoemotional disorders in male patients diagnosed with prostate 
carcinoma and receiving cancer treatment. The study’s patients were recruited at the 
Oncological Hospital in Wieliszew, Poland, between September 2016 and December 
2017. The study was performed in 166 male patients diagnosed with prostate cancer. 
Two standardized questionnaires were used in the study, EORTC QLQ-C30 and 
QLQ-PR25, for patients with prostate cancer, developed by the European Quality of 
Life Group. The type and stage of cancer treatments were a significant contributor to 
feeling tense, worried, depressed, and irritable among the study patients. The stage 
of treatment, however, caused a negative effect on these parameters. Pretreatment 
patients declared high or very high satisfaction with their sexual life, while post-
treatment patients and those on cancer treatment indicated low sexual satisfaction. 
However, a feeling of embarrassment during intimate contact as well as erectile 
disorders correlated both with the type and stage of cancer treatment. Our results 
show that affected male patients should be offered continuous psychological care, 
especially those waiting for treatment and those on treatment.
Keywords: prostate carcinoma, quality of life, sexual disorders, psychoemotional 
disorders, oncological treatment
1. Background
Prostate carcinoma (PCa) is one of the most frequent malignant cancers in the 
male population. In terms of incidence, it is second only to lung cancer. Treatment 
of prostate carcinoma includes surgical procedures, radiotherapy, chemotherapy, 
and hormone therapy, and all these procedures have an adverse impact on the sexual 
functioning of men. Erectile disorders, loss of sex drive, and difficulty achieving 
orgasm are the most frequent problems in the course of disease and its treatment 
[1, 2]. The existing studies show that few men with sexual dysfunctions and on 
cancer treatment seek the help of a specialist to effectively eliminate such problems 
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[3]. Other studies show that this population of patients frequently experiences, as a 
result of changes in the sexual functioning, fear, anxiety, and depression as well as 
loss of male identity [4]. Therefore, psychological care and social support (includ-
ing their closest family and friends) are increasingly considered an important 
component of many chronic diseases. At the same time, studies suggest that men 
who find no emotional support in their social environment are more exposed to 
depression and more seldom achieve positive mental well-being [5]. Additionally, it 
was demonstrated that specialist (psychological) and social support are associated 
with significantly reduced mental stress and general improvement of the quality of 
life in the population of men with prostate carcinoma.
2. Material and methods
The study’s patients were recruited at the Oncological Hospital in Wieliszew, 
Poland,between September 2016 to December 2017. The study was performed 166 
male patients diagnosed with prostate cancer. The study included men who gave 
informed, written consent to participate. In the study was used two standard-
ized questionnaire: EORTC QLQ-C30 (version 3.0) and QLQ-PR25 for patients 
with prostate cancer, developed by the European Quality of Life Group. These 
questionnaires are used to research the summary sense of health and evaluation of 
performance in various dimensions (physical, emotional and social) and typical 
symptoms of prostate cancer.
2.1 Ethics
The Ethical Committee consent for the presented research is not required. 
According to the statement of the Ethical Committee of the Medical University 
of Warsaw: “The Committee does not provide opinions on surveys, retrospec-
tive studies, or other non-invasive research” (Detailed information and tem-
plates of documents of Ethics Committee of Medical University of Warsaw 
(Accessed 2016-10-01): http://komisjabioetyczna.wum.edu.pl/content/
szczeg%C3%B3%C5%82owe-informacje-orazwzory-dokument%C3%B3w).
3. Results
The study included 166 men. The mean age of participants was 67.66 ± 7.25 (range: 
51–84 years). The main part of population taking part in the study comprised people 
aged 65–69 years (37.35%). The majority (68.7%) of patients, during the study, were 
undergoing the treatment. The treatment analysis revealed that 66% of the par-
ticipants subjected to radiotherapy. Smaller numbers were found for the remaining 
therapy: 16.9% hormonal therapy, 2.38% surgery (4.8%), and 3.6% chemotherapy. 
The proportion of patients was treated with combined therapies: radiotherapy + sur-
gery (8.33%), radiation + hormonal therapy (6.03%), and surgery + hormonal + che-
motherapy (2.41%). The characteristics of the patients are shown in Table 1.
3.1 Emotional problems
No correlation was found between the study variable and the health status or 
quality of life score or the age of patients. However, feeling tense may be affected 
by the type of treatment administered to the patients (Chi2 = 94.15, p = 0.0000; 
R = 0.21, p > 0.05). The results of statistical analysis show that the greatest number 
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of men who declared that they did not feel tense during the last week underwent 
radiotherapy (58.82%) or radiotherapy and surgical treatment (57.14%). On the 
other hand, all the patients who received surgical treatment, chemotherapy, and 
hormone therapy indicated that they felt very tense. A similar correlation was 
shown in relation to the stage of cancer treatment (Chi2 = 19.73, p = 0.00310; 
R = −0.00, p > 0.05).
Feeling worried also depends on the stage of cancer treatment (Chi2 = 21.67, 
p = 0.00139; R = 0.20, p > 0.05). Posttreatment patients significantly more often 
indicated that they did not worry during the last week (56.25% of the group), while 
patients waiting for treatment more often declared to feel worried or very worried  
(40% of the group in total). Similarly to the question about feeling tense, the results 
show that feeling worried affected all the patients undergoing surgical treatment, 
chemotherapy, and hormone therapy. Patients receiving radiotherapy (27.45% of the 
group) or both radiotherapy and surgical treatment (28.57%) (Chi2 = 69.06, p = 0.0000; 
R = 0.13, p > 0.05) most often indicated that they did not feel worried. However, no 
correlation was found between feeling worried and the patients’ age (p > 0.05).
The impact of health status on patients feeling worried was also insignificant 
(Chi2 = 44.87, p = 0.00043; R = −0.04, p > 0.05), although it could be observed 
that patients with a greater health status score more rarely indicated that they felt 
worried. A similar correlation was observed with regard to the quality of life score 
(Chi2 = 43.38, p = 0.00071; R = −0.11, p > 0.05).
None of the patients who received cancer treatment declared to be very or 
significantly irritable. However, these responses were indicated by 40% of the 
patients waiting for treatment (Chi2 = 16.24, p = 0.01251; R = −0.03, p > 0.05). The 
Characteristics of the patients in the survey Number of patients (N = 166 (100%))
Age
 <54 2 (1.2)
 55–59 16 (9.6)
 60–64 26 (15.7)
 65–69 62 (37.3)
 70–74 24 (14.5)
 75–79 24 (14.5)
 >80 12 (7.2)
Stage of oncology treatment
 Before treatment 20 (12)
 During the course of treatment 114 (68.7)
 After treatment 32 (19.3)
Type of oncology treatmenta
 Surgery 8 (4.8)
 Radiotherapy 110 (66)
 Hormonal therapy 28 (16.9)
 Chemotherapy 6 (3.6)
 I do not know 20 (12)
aThe question with multiple answers.
Table 1. 
Characteristics of the group of patients participating in the survey.
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least irritability were experienced by patients undergoing radiotherapy or surgi-
cal treatment, the greatest irritability—by patients receiving surgical treatment, 
chemotherapy, and hormone therapy (Chi2 = 69.05, p = 0.0000; R = 0.06, p > 0.05). 
On the other hand, no correlation was found between feeling irritable and the 
patients’ age, health status, or quality of life score (p > 0.05 for all the cases).
Even though no correlation was found between the age or the quality of life score 
and feeling depressed (p > 0.05), a statistical analysis of the study results showed 
that feeling depressed may depend on the patient’s health status (Chi2 = 33.34, 
p = 0.01517; R = −0.36, p = 0.00681). Patients with a lower health status score much 
more often declared that they felt depressed during the last week.
As with the above-described correlations, feeling depressed is also corre-
lated (although weakly) with the stage of the patient’s treatment (Chi2 = 13.11, 
p = 0.04122; R = 0.06, p > 0.05) and the type of treatment (Chi2 = 67.37, 
p = 0.0000; R = 0.11, p > 0.05). No depression was most often indicated by patients 
who underwent cancer treatment (56.25% of this group), radiotherapy (45.10%), or 
both radiotherapy and surgery (42.86%).
The greatest difficulties in remembering were indicated by pretreatment 
patients (30% of responses “to a significant degree” and “very much” in this 
group of patients compared to 7% of the patients on treatment and 0% of the 
posttreatment patients) (Chi2 = 19.25, p = 0.00376; R = −0.07, p > 0.05) and those 
receiving surgical treatment, hormone therapy, and chemotherapy (100% of 
the group) (Chi2 = 97.20, p = 0.0000; R = 0.08, p > 0.05). Additionally, a strong 
correlation was found between difficulties in remembering and health status score 
(Chi2 = 34.89, p = 0.00976; R = −0.45, p = 0.0000). The higher health status score is 
correlated with an absence of difficulties in remembering or only slight difficulties 
in remembering. Serious and very serious difficulties in remembering were indi-
cated only by the patients with a health status score less than 5. A similar correlation 
exists with regard to the quality of life score. Patients with the lowest quality of life 
score did not indicate any considerable or significant problems in remembering. 
Patients who declared frequent problems in remembering had a lower quality of life 
score (Chi2 = 32.30, p = 0.02024; R = −0.26, p = 0.00071). However, no correlation 
was found between difficulties in remembering and the patients’ age (p > 0.05) 
(Tables 2 and 3).
3.2 Urination problems
Among the study patients, 12% of them frequently passed urine during the 
day. This problem has a significant impact on the quality of life of the patients 
Emotional problems Question 
no.a
Number of patients (N = 166) N (%)
Not at 
all
A little Quite a 
bit
Very 
much
Feeling circuit 21 86 (51.8) 72 (43.4) 4 (2.4) 4 (2.4)
Feeling worried 22 40 (24.1) 98 (59) 22 (13.3) 6 (3.6)
The feeling of annoyance 23 68 (40.9) 70 (42.2) 22 (13.3) 6 (3.6)
Feeling depressed 24 70 (42.2) 72 (43.4) 18 (10.8) 6 (3.6)
Difficulty in remembering 25 84 (50.6) 68 (41.0) 10 (6) 4 (2.4)
aNumber of issues in accordance with the questionnaire QLQ-C30.
Table 2. 
Emotional problems of the patients.
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(Chi2 = 30.86, p = 0.02988; R = −0.24, p = 0.02967). Patients with no problems with 
frequent urination during the day had a higher quality of life score compared to 
patients who had to urinate very frequently during the day. Similar but significantly 
weaker correlation was identified between the quality of life score and frequent 
nighttime urination (Chi2 = 33.42, p = 0.01484; R = −0.11, p > 0.05) or the quality 
of life score and the need to hurry into the toilet before passing urine (Chi2 = 33.83, 
p = 0.01321; R = 0.05, p > 0.05).
Over 60% of the patients indicated that having to get up at night to urinate 
affected their night’s rest. This problem had a strong impact on how the patients 
assessed their quality of life (Chi2 = 54.09, p = 0.0000; R = −0.52, p = 0.0000). The 
quality of life score was also affected by problems related to going out of the house 
due to the fact that the patients had to be close to a toilet. Problems with involun-
tary release of urine were indicated by nearly half of the patients, and 17% of the 
patients considered this problem to be considerable or significant. This group of 
patients usually has a lower quality of life score, even though this correlation is not 
strong (Chi2 = 43.87, p = 0.00060; R = −0.21, p > 0.05). Nearly 50% of the patients 
declared to have painful urination; however, no correlation was found between 
pain and the quality of life score (p > 0.05). Among the study patients, 32.53% 
of them use protection products against urinary incontinence. Using this type of 
protection was considered a nuisance only by 40% of the patients and affected 
how they perceived their quality of life (Chi2 = 55.22, p = 0.00001; R = −0.23, 
p = 0.03563). Generally, limitations related to everyday functioning due to urina-
tion problems were indicated by nearly 40% of men. This effect was considered 
significant or highly significant by 12% of the patients. However, the correlation 
between the limitation of everyday activities and the quality of life score is insig-
nificant (Chi2 = 38.50, p = 0.00332; R = 0.17, p > 0.05). Detailed results are given in 
Tables 4 and 5.
3.3 Sexual activity of the study patients
Nearly 60% of the patients indicated that they experienced a sense of loss of 
manhood due to the disease or its treatment. Younger patients more often declared 
a strong or very strong sense of loss of manhood (100% of patients under the age 
of 54 years, 62.5% of patients aged 55 to 59 compared to 50% of patients aged 
75–79 or 16.67% of patients over the age of 80 years) (Chi2 = 40.61, p = 0.00172; 
R = 0.09, p > 0.05). A sense of loss of manhood was mostly declared by the post-
treatment patients or the patients on cancer treatment (the responses “very strong” 
and “strong” were given by 57.89 and 75% compared to 30% of patients waiting 
Emotional problems Question no.a Quality of life
p-value R-Spearmanb
Feeling circuit 21 0.727 —
Feeling worried 22 0.000 —
The feeling of annoyance 23 0.353 —
Feeling depressed 24 0.174 —
Difficulty in remembering 25 0.020 −0.364
aNumber of issues in accordance with the questionnaire QLQ-C30.
bSignificant correlation p < 0.05.
Table 3. 
Emotional problems of the patients and felt the quality of life.
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for treatment) (Chi2 = 14.74, p = 0.02230; R = 0.15, p > 0.05). The type of treat-
ment had no impact on a sense of loss of manhood (p > 0.05). Nearly half of the 
patients had no interest in sexual life during the last 4 weeks (45.8%). No interest 
in having sex was mostly indicated by elderly patients over 70 years of age. None 
of the patients under 60 years of age selected the response “none” (Chi2 = 41.22, 
Problems with urination Question 
no.a
Number of patients (N = 166) N (%)
Not at all A little Quite a 
bit
Very 
much
Frequent urination during the day 31 14 (8.4) 76 (45.8) 56 (33.7) 20 (12.1)
Frequent urination during the night 32 22 (13.3) 82 (49.4) 44 (26.5) 18 (10.8)
The need to accelerate the toilet before 
urinating
33 48 (28.9) 64 (38.6) 28 (16.9) 26 (15.7)
The impact of waking up at night to night 
stay
34 56 (33.7) 64 (38.6) 36 (21.7) 10 (6)
Problems with leaving home because of the 
frequent need to use the toilet
35 80 (48.2) 60 (36.1) 14 (8.43) 12 (7.2)
Involuntary leakage of urine 36 86 (51.81) 52 (31.33) 18 (10.8) 10 (6)
Pain when urinating 37 84 (50.6) 70 (42.2) 6 (3.6) 6 (3.6)
Problems with wearing protection against 
incontinence
38b 32 (59.3) 16 (29.6) 6 (3.6) 0 (0)
Limitation of daily activities by problems 
with urination
39 102 (61.5) 44 (26.5) 14 (8.4) 6 (3.6)
aNumber of issues in accordance with the questionnaire QLQ-C30.
bQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
Table 4. 
Problems with urinating in the group of patients studied.
Problems with urination Question no.a Quality of life
p-value R-Spearmanb
Frequent urination during the day 31 0.029 0.239
Frequent urination during the night 32 0.014 —
The need to accelerate the toilet before urinating 33 0.013 —
The impact of waking up at night to night stay 34 0.000 −0.518
Problems with leaving home because of the frequent need to 
use the toilet
35 0.002 −0.314
Involuntary leakage of urine 36 0.000 —
Pain when urinating 37 0.060 —
Problems with wearing protection against incontinence 38c 0.000 −0.231
Limitation of daily activities by problems with urination 39 0.003 —
aNumber of issues in accordance with the questionnaire QLQ-C30.
bDemonstrated statistically significant correlations only; p < 0.05.
cQuestion applies only to patients wearing protection against urinary incontinence (N = 54).
Table 5. 
Problems with urination and the evaluation of the quality of life for patients.
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p = 0.00142; R = 0.08, p > 0.05). As regards the stage of oncological treatment, 
43.75% of the posttreatment patients and 52.63% of the patients on treatment 
had no interest in sex. Among the patients waiting for treatment, it was 10% 
(Chi2 = 26.89, p = 0.00015; R = 0.18, p > 0.05). Patients undergoing radiotherapy 
or radiotherapy and hormone therapy showed least interest in sexual life, while 
patients undergoing surgical treatment or surgical treatment, chemotherapy, 
and hormone therapy—greatest interest in sexual life (Chi2 = 55.75, p = 0.00001; 
R = 0.09, p > 0.05). Nearly 60% of the patients were not sexually active during the 
last 4 months, and there is no correlation between the level of sexual activity and 
the patient’s age (p > 0.05). The posttreatment patients and those on treatment were 
least sexually active (the response “none” was indicated by 64.91% and 50% of the 
patients in these groups, respectively). Among the patients waiting for treatment, 
30% of the patients declared lack of sexual activities (Chi2 = 20.32, p = 0.00234; 
R = 0.12, p > 0.05). Based on an analysis of the type of treatment, it can be shown 
that patients who underwent surgical treatment or chemotherapy and hormone 
therapy were characterized by greatest sexual activity (100% in both cases). In the 
other treatment categories, the percentage of sexually active men was about 40% 
(Chi2 = 46.43, p = 0.00026; R = 0.04, p > 0.05).
Among the patients who were sexually active during the last 4 months, 37% 
of them were satisfied or very satisfied with their sexual life. High or very high 
satisfaction with sexual life was indicated by 50% of the patients prior to cancer 
treatment, 12.5% of the posttreatment patients, and 7% of the patients on treat-
ment (Chi2 = 23.89, p = 0.00239; R = 0.33, p = 0.00228). The type of treatment also 
affected satisfaction with sexual life (Chi2 = 76.52, p = 0.0000; R = 0.05, p > 0.05). 
Patients undergoing surgical procedures, hormone therapy, and chemotherapy 
were very satisfied with their sexual life, while patients undergoing only surgical 
procedures or surgical procedures combined with radiotherapy declared low or no 
satisfaction with their sexual life. The patient’s age has no effect on his satisfaction 
with sexual life (p > 0.05).
Difficulties with achieving or maintaining erection were declared by 73.3% of 
the sexually active patients, regardless of their age (p > 0.05). Significant or consid-
erable difficulties were most often indicated by patients on cancer treatment (30% 
of the patients) (Chi2 = 16.71, p = 0.03328; R = 0.29, p = 0.00839) or patients under-
going radiotherapy (43.33%) (Chi2 = 61.98, p = 0.00003; R = −0.01, p > 0.05).
Difficulties with ejaculation were declared by 66.7% of the sexually active 
patients, even though these problems are not related to the patients’ age (p > 0.05). 
Problems with ejaculation were least frequent among patients prior to cancer treat-
ment (50%), while all the posttreatment patients reported having such difficulties 
(Chi2 = 34.44, p = 0.00003 R = 0.27, p = 0.01530). Patients who received surgical 
treatment, hormone therapy, or both radiotherapy and hormone therapy had no 
difficulties with ejaculation (Chi2 = 45.58, p = 0.00496; R = 0.04, p > 0.05).
A feeling of embarrassment during intimate contact was indicated only by 
56.7% of the sexually active patients. The above variable was not age-dependent 
(p > 0.05). However, a feeling of embarrassment was correlated with the stage of 
cancer treatment (Chi2 = 16.85, p = 0.03164; R = 0.30, p = 0.00526) and the type of 
treatment (Chi2 = 40.05, p = 0.02111; R = 0.00, p > 0.05). Embarrassment during 
sexual contact was not experienced by pretreatment patients, patients receiving 
surgical treatment, hormone therapy or radiotherapy in combination with hormone 
therapy.
It should be pointed out that none of the discussed aspects of sexual activity, in 
relation to all the patients or only those sexually active during the last 4 months, 
had no impact on the quality of life score (p > 0.05 for all cases). The above results 
are shown in Tables 6 and 7.
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4. Discussion
Sexuality is an important aspect of human life, and emotions related to sexual 
activity influence mental well-being, relationship, or how we see ourselves. Sexual 
function disorders (e.g., erectile dysfunction) caused by prostate carcinoma 
significantly reduces the quality of life of men [6–8]. Cancer treatment is also 
related to reduced sex drive and penile dysfunction manifesting itself through, for 
example, reduced ability to have an orgasm, erectile disorders, or urinary inconti-
nence [9, 10]. The above changes in sexual functions are also related to anxiety and 
depression, challenges in everyday life, and disrupted intimate relations with the 
patient’s partner [11–14]. However, other studies indicated that many patients with 
Sexual activity Question 
no.a
Number of patients (N = 166) N (%)
Not at 
all
A little Quite a 
bit
Very 
much
Feeling perdition masculinity 49 26 
(15.7)
44 
(26.5)
40 
(24.1)
56 
(33.7)
The interest in sexual intercourse 50 72 
(45.8)
48 
(28.9)
20 
(12.1)
22 
(13.3)
The degree of sexual activity 51 96 
(57.8)
34 
(20.5)
18 
(10.8)
18 
(10.8)
Satisfaction with sexual intercourse 52b 28 
(46.8)
10 
(16.7)
8  
(13.3)
14 
(23.3)
Difficulty getting or maintaining an 
erection
53b 16 
(26.7)
12 
(20.0)
14 
(23.3)
18 
(30.0)
Difficulties with ejaculation 54b 20 
(33.3)
12 
(20.0)
6 
(10.0)
22 
(36.7)
The feeling of embarrassment during 
intimacy
55b 26 
(43.3)
4  
(6.7)
12 
(20.0)
18 
(30.0)
aNumber of issues in accordance with the questionnaire QLQ-C30.
bQuestion applies only to patients who are sexually active within the last 4 weeks (N = 60).
Table 6. 
Sexual activity patients.
Problems with urination Question 
no.a
Quality of life
p-value R-Spearmanb
Feeling perdition masculinity 49 0.134 —
The interest in sexual intercourse 50 0.420 —
The degree of sexual activity 51 0.384 —
Satisfaction with sexual intercourse 52c 0.509 —
Difficulty getting or maintaining an erection 53c 0.142 —
Difficulties with ejaculation 54c 0.361 —
The feeling of embarrassment during intimacy 55c 0.585 —
aNumber of issues in accordance with the questionnaire QLQ-C30.
bDemonstrated statistically significant correlations only; p < 0.05.
cQuestion applies only to patients who are sexually active within the last 4 weeks (N = 60).
Table 7. 
Sexual activity and quality of life of the patients.
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prostate carcinoma suffer at a later stage from complications in the course of disease 
and its treatment [15, 16].
On the other hand, feeling worried also depends on the stage of cancer treat-
ment. Patients waiting for treatment more often declared to be worried (to a 
considerable or significant extent) than posttreatment patients. At the same time, 
all the patients who received surgical treatment, chemotherapy, and hormone 
therapy indicated that they felt worried. No fatigue was most often indicated 
by patients receiving radiotherapy or both radiotherapy and surgical treatment. 
However, health status also had an insignificant impact on patients feeling worried, 
even though patients with a greater quality of life score more rarely declared that 
they felt worried. Other studies suggest that hot flushes were strongly associated 
with insomnia and they caused depression particularly in the group of elderly men 
receiving hormone therapy [17–19]. However, Yang et al. [20] determined that 
physical condition of cancer patients was closely related to the fatigue index and 
it was also the major factor affecting the quality of life of patients. Other studies 
showed that regular monitoring of fatigue and its elimination could improve physi-
cal condition of patients and therefore improve their quality of life [21, 22]. It is 
well documented in the literature that all types of cancer treatment, and especially 
chemotherapy, are associated with side effects such as fatigue, depression, pain, and 
many other problems [23–25]. Urination problems during the day had a significant 
negative impact on the quality of life of patients. A similar but significantly weaker 
correlation was identified between the quality of life score and frequent nighttime 
urination or the quality of life score and the need to hurry into the toilet before 
passing urine. At the same time, having to get up frequently at night to urinate 
affects the night’s rest and has a strong impact on how patients perceive their quality 
of life. However, pain during urination was declared by half of the patients, and 
no correlation was found between pain and the quality of life score. Vogl et al. [26] 
showed that an insignificant number of men undergoing cancer treatment had 
certain difficulties passing urine which were reversible over time. However, Arscott 
et al. [27] demonstrated that urinary tract symptoms are frequently associated with 
sexual disorders after surgical treatment and radiotherapy.
An analysis of the sexual activity of the study patients showed that younger men 
more often indicated a strong or very strong sense of loss of manhood due to the 
disease or its treatment. A sense of loss of manhood was mostly declared by posttreat-
ment patients or patients on cancer treatment. The type of treatment had no impact on 
a sense of loss of manhood (p > 0.05). In one of their studies, Zaider et al. [1] 
found that 1/3 of the male patients lost an important aspect of their manhood as a 
side effect of disease treatment, which proved to be a significant obstacle to their 
sexuality. O′ Shaughnessy et al. [2] determined that the affected patients may not be 
fully aware of their sexual losses. In another study, an inability to perform sexually 
by men diagnosed with a chronic disease was described as a source of suffering  
[28, 29]. Harrington et al. [30] argued that a body image is an important aspect of 
human quality of life, especially in patients diagnosed with cancer. On the other 
hand, the loss of sexual functions in posttreatment patients may undermine their 
concept of manhood [31, 32].
Patients undergoing surgical treatment or chemotherapy and hormone therapy 
showed the least interest in sexual life. On the other hand, there is no correlation 
between the level of sexual activity and the patients’ age (p > 0.05). Posttreatment 
patients and patients on treatment were least sexually active. Additionally, tak-
ing into account the type of treatment, patients receiving surgical treatment or 
chemotherapy and hormone therapy were characterized by greatest sexual activ-
ity. Another study demonstrated that unwillingness to meet people or have sex is 
more common among men treated for cancer and it is most likely best observable 
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in men with prostate carcinoma who receive hormone therapy. The study at hand 
showed that more than 95% of men treated with this method reported subjective 
sex drive disorders [6]. However, DiBlasio et al. [13] demonstrated that more than 
95% of men receiving hormone therapy reported libido and sex drive disorders. The 
loss of libido is frequently observable in patients with Hodgkin disease (Hodgkin 
lymphoma), where more than 40% of men reported this side effect [14]. The loss of 
libido was also observable in patients with hematologic cancers [15, 16]. Different 
results were obtained by Olsson et al. [33] who argued that low libido may originate 
from fatigue and/or feeling unwell. Furthermore, this condition may be associated 
with the stage of disease and intensive cancer therapy.
Our study showed that among sexually active men, pretreatment and posttreat-
ment patients as well as patients on cancer treatment were satisfied or very satisfied 
with their sexual life. The level of satisfaction with sexual life was also affected by 
the type of treatment, while the patients’ age had no effect on their satisfaction with 
sexual life (p > 0.05). Given that good mental well-being depends on many factors, 
it cannot be stated without ambiguity that men can achieve sexual satisfaction only 
through a successful sexual intercourse. However, for men with chronic erectile 
disorders, inability to achieve penetration may be a source of considerable difficul-
ties and frustration. For example, couples open to changes and willing to cooperate 
were able to adapt to the needs of the affected partner and to accept the side effects 
of cancer treatment [34–36].
However, our studies showed that men receiving treatment or radiotherapy 
have considerable or major difficulties in achieving or maintaining erection. Other 
study [3] shown that erectile disorders were observed in 77% of men treated for 
prostate carcinoma who underwent radical prostatectomy and in 60% of patients 
receiving radiotherapy. It was also observed that post-radiotherapy erectile 
disorders were usually delayed (1 or 2 years after therapy) in contrast to a quick 
response achieved in a group of patients immediately after surgical treatment [28]. 
Erectile disorders were also observed in other populations, for example, in patients 
treated for anal diseases or rectal and testicular cancer [9, 11]. Difficulties with 
ejaculation were not correlated with the age of patients (p > 0.05). Problems with 
ejaculation were least frequent among patients prior to cancer treatment, while 
all the posttreatment patients reported having such difficulties. Patients who 
received surgical treatment, hormone therapy or both radiotherapy and hormone 
therapy had no problems with ejaculation. Sullivan et al. [37] determined that 
radiotherapy, especially if it is focused on the prostate gland, may be associated 
with anejaculation (inability to ejaculate). A study in 364 men diagnosed with 
prostate carcinoma and undergoing radiotherapy showed that as many as 72% of 
the patients experienced anejaculation. However, elderly men and patients receiv-
ing lower doses of radiation were less exposed to this side effect. This situation may 
lead to an intentional avoidance of orgasm by men suffering from prostate carci-
noma. On the other hand, Wassersug et al. [12] noticed that the lack of ejaculation 
in men having homosexual relations caused particular discomfort. However, in our 
study, a feeling of embarrassment during intimate contact (in sexually active men) 
was not correlated with age but with the stage of cancer treatment and the type 
of therapy.
Embarrassment during sexual contact was not experienced by pretreatment 
patients, patients receiving surgical treatment, hormone therapy, or radiotherapy 
combined with hormone therapy. Additionally, none of the discussed aspects of 
sexual activity, in relation to all the patients or only those sexually active during 
the last 4 months, had no impact on the quality of life score (p > 0.05 for all cases). 
Harrington et al. [38] showed that men who underwent hormone therapy are 
exposed to verbal abuse due to changes in their appearance as a side effect of the 
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therapy (weight gain, loss of muscle mass, reduced hair, gynecomastia). Reduced 
embarrassment and dissatisfaction with one’s own body was reported by men 
with the same diagnosis but undergoing treatment other than hormone therapy. 
A feeling of embarrassment is also caused by changes in body weight (weight gain 
or weight loss) which in turn affects the image of one’s own manhood [39, 40]. 
However, problems related to the body image are not necessarily focused only 
on the penis. In male patients treated for colorectal cancer, intestinal stoma was 
associated not only with erectile disorders but also with a feeling of shame before 
themselves and their partner.
5. Conclusions
1. Despite the existing psychoemotional disorders, no correlation was 
found between the age of patients and feeling tense, worried, irritable, or 
depressed. Additionally, complaints reported by sexually active patients 
showed no correlation between age and a sense of loss of manhood, erectile 
disorders, satisfaction with sexual life, or embarrassment during intimate 
contact.
2. The type and stage of cancer treatment (mostly prior to therapy) had a 
significant impact on feeling tense, worried, depressed, and irritable. It 
was also shown that feeling depressed affects the patient’s health status to a 
considerable extent. Our results show the urgent need to provide the patients 
with continuous psychological care, especially those waiting for treatment and 
those on treatment.
3. The method of treatment had no major impact on a sense of loss of manhood 
and the degree of sexual activity, while the stage of treatment (posttreat-
ment patients and patients on treatment) had a negative effect on these 
parameters. Pretreatment patients declared high or very high satisfaction 
with their sexual life, while posttreatment patients and those on cancer 
treatment indicated low sexual satisfaction. However, feeling embarrassed 
during intimate contact as well as erectile disorders correlated both with the 
type and stage of cancer treatment. An analysis of the sexual functioning of 
prostate carcinoma men suggests that the patients should be under the care 
of a clinical sex therapist.
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